Arizona Tribune - Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value

Strategic Rationale: Accelerating Growth Through Independence

The Exousia AI transaction with LMMY is the first strategic initiative in Exousia Pro's long-term plan to unlock significant value and establish its core divisions as independent, publicly traded entities. The sale addresses immediate operational and growth objectives:

• Enhanced Corporate Credibility: The transaction immediately places Exousia AI onto the LMMY platform, establishing it as an audited SEC Reporting Company. This essential step provides the necessary institutional credibility to pursue large-scale partnerships, collaborations, and capital that were previously unavailable due to MAJI's unaudited, non-reporting OTC status.

• Non-Dilutive Capital Access: By realigning Exousia AI to LMMY, a new, clean public platform is created specifically for Exousia AI to raise necessary expansion capital, ensuring this funding is non-dilutive to MAJI shareholders.

• Recruitment and Branding: The new platform allows Exousia AI to operate independently of MAJI's former trade name ("Marijuana Inc."), thereby eliminating brand constraints that previously hindered efforts to attract top-tier talent, certain institutional partners and significant capital sources.

MAJI Benefits: Maximizing Value and Future Uplisting Potential

Exousia Pro has structured the sale to retain significant long-term value and strategic control:

• Substantial Equity and Influence: MAJI has received approximately 51% of the shares of LMMY, thereby securing its position as the largest shareholder of LMMY and ensuring continued influence over the direction and utilization of the core exosome technology.

• Officer and Directors: Matthew Dwyer, President of MAJI shall be the initial sole Officer and Director of LMMY; Mr. Dwyer will continue to perform his obligations with MAJI.

• Recurring Revenue Stream: MAJI has entered into a licensing agreement with LMMY, providing for annual licensing fees and ongoing royalties based on the future commercial success of the technology to be exploited by LMMY through Exousia AI.

• Tangible Valuation: LMMY's status as an SEC Reporting Company provides a clear public platform for a fairer, tangible valuation of the Glioblastoma and cancer treatment intellectual property, directly benefiting MAJI's shareholders in this division.

• Pathway to Senior Exchange: LMMY intends to begin the process of pursuing a NASDAQ uplisting as its partnerships and capital evolve. This will further validate the underlying technology and enhance MAJI's equity stake.

• Non-Dilutive Financing Lever: The LMMY shares are a critical, non-dilutive asset that can be strategically leveraged to secure financing for MAJI's own corporate objectives, including its plan to pursue its own uplisting to a higher exchange.

Forward-Looking Share Strategy

The LMMY shares will be retained by MAJI in the near term to support the company's strategic goals, including leveraging the shares to pursue non-dilutive capital initiatives and to meet the requirements for MAJI's planned uplisting to a higher exchange such as NASDAQ. Management will evaluate the possibility of a share dividend as part of its 2026 roadmap, which also includes additional planned mergers for other operating divisions.

Post-Merger Capital Structure of LMMY (Pro Forma)

"This transaction represents a strategic acceleration for both organizations," stated Matt Dwyer, President of Exousia Pro, Inc. "This transaction also immediately unlocks Exousia AI's full potential by placing it onto a clean, SEC-reporting platform, positioning it to rapidly secure the capital needed to advance its critical Glioblastoma and rare cancer treatments. We are convinced that this powerful structure places MAJI and its shareholders into a significantly better position from which to benefit from Exousia AI's anticipated future success, without enduring any further dilution."

About Exousia Pro, Inc.

Exousia Pro, Inc. (EXO), a leader in exosome-based biotechnology, develops and manufactures mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. EXO's breakthrough platform enables the custom production of exosomes with enhanced genetic functionality, capable of selectively targeting specific cells to address diseases with significant unmet medical needs. These engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including Glioblastoma and pancreatic cancer, thereby improving patient responsiveness to anticancer therapies. The same platform technology also holds promise for treating a broad spectrum of viral infections.

For more information, please visit: www.exousiapro.com

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
X: @Exousia_Pro

Investor Relations
[email protected]

SOURCE: Exousia Pro, Inc.

View the original press release on ACCESS Newswire

D.Lopez--AT